

Careteq Limited

ACN 612 267 857

Level 10, 99 Queen St Melbourne 3000 info@careteq.com.au Phone: 1300 110 366

International: +613 8866 5594

29th November 2022

The Manager

Market Announcements Platform

Australian Securities Exchange Limited

CARETEQ LIMITED 2022 ANNUAL GENERAL MEETING PRESENTATION

Careteq Limited (ASX: CTQ) ("Careteq" or the "Company") is holding its 2022 Annual General Meeting (AGM) today, Tuesday 29 November 2022 at 10.00am (AEDT) and is pleased to attach its AGM Presentation.

The Board has authorised this announcement for release to the ASX.

-ENDS-

About Careteq Limited

Careteq is an Australian-headquartered health-tech company that has developed and commercialised a suite of products that sit on its proprietary SaaS-based Assistive Living Technology platform for use by the elderly, disabled and vulnerable individuals. Its products and services, which improve outcomes for patients and their carers while increasing productivity, are sold in Australia and internationally through industry leading distributors and specialist retailers. Careteq generates revenues from recurring platform subscriptions, contracted medication management services and sales of its innovated range of sensors and devices that detect falls or unusual behaviour, monitor patient health, provides SOS emergency call functionality and deliver medication reminders. Careteq is using its early-mover advantage in the Assistive Living Technology sector to revolutionise aged and disability care. For more information about Careteq, visit https://www.careteq.com.au/.

Subscribe to receive investor updates by emailing: investors@careteq.com.au

For investor and media enquiries, please contact:

Brendon Lau

E: brendon@vantagepointpartners.com.au

M: +61 409 341 613



Disclaimer and Important Notices

This presentation has been prepared by Careteq Limited ACN 612 267 857 (**Company**). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does not purport to be all-inclusive, comprehensive or to contain all of the information that may be relevant, or which a prospective investor may require in evaluations for a possible investment in the Company. Prospective investors should not rely on the information contained in this presentation, and must satisfy themselves as to the accuracy of all such information. This presentation has been prepared based on information available at the time of preparation and is subject to change without notice. In receiving this presentation, each recipient agrees to the foregoing terms and conditions, including any modifications to them. No person is under any obligation to update this presentation at any time after its release.

This presentation is provided for general information purposes only. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of securities in the Company in any jurisdiction. It is not a prospectus, product disclosure statement, pathfinder document or any other type of public offer disclosure document for the purposes of the Corporations Act 2001 (Cth) (Corporations Act) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission. It should not be relied upon by the recipient in considering the merits of the Company or the acquisition of shares in the Company.

This presentation does not constitute investment or financial product advice. It is not intended to be used as the basis for making a financial decision, nor is it intended to constitute legal, tax, accounting or other advice. This presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, the recipient should consider its own financial situation, objectives and needs, and conduct its own independent investigation and assessment of the contents of this presentation, including obtaining investment, legal, tax, accounting and such other advice as it considers necessary or appropriate. Any references to or explanations of legislation, regulatory issues, benefits or any other legal commentary (if any) are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. The information in this presentation has been obtained from and based on sources believed by the Company to be reliable. Past performance is not an indication of future performance.

This presentation may contain forward-looking statements, guidance, forecasts, estimates, prospects, projections or statements in relation to future matters that may involve risks or uncertainties and may involve significant items of subjective judgement and assumptions of future events that may or may not eventuate (Forward Statements). Forward Statements can generally be identified by the use of forward looking words such as "anticipate", "estimates", "will", "should", "could", "may", "expects", "plans", "forecast", "target" or similar expressions. Forward Statements including indications, guidance or outlook on future revenues, distributions or financial position and performance or return or growth in underlying investments are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. To the extent that certain statements contained in this presentation may constitute 'Forward Statements' or statements about forward looking matters, then the information reflects the Company's (and no other party's) intent, belief or expectations as at the date of this presentation. No independent third party has reviewed the reasonableness of any such statements or assumptions. None of the Company, its related bodies corporate and their respective officers, directors, employees, advisers, partners, affiliates and agents (together, the Careteq Parties) represent or warrant that such Forward Statements will be achieved or will prove to be correct or gives any warranty, express or implied, as to the accuracy, completeness, likelihood of achievement or reasonableness of any Forward

Statement contained in this presentation. Except as required by law or regulation, the Company assumes no obligation to release updates or revisions to Forward Statements to reflect any changes. Recipients should form their own views as to these matters and any assumptions on which any of the Forward Statements are based and not place reliance on such statements.

All dollar values are in Australian dollars (\$ or A\$) unless otherwise stated.

An investment in the Company's securities is subject to known and unknown risks, many of which are beyond the control of the Company, including factors and risks specific to the industry in which the Company operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. The Company does not guarantee any particular rate of return or the performance of the Company, nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes may have on the Company.

By accepting this presentation the recipient agrees to keep permanently confidential all information that it contains. It should not be made available to any other third party without the prior written approval of the Company. Furthermore, no contact should be made with the Company or any of the aforementioned companies customers, suppliers or shareholders without the express permission of the Company.

The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. The presentation is not an offer of securities in the Company for subscription, purchase or sale in any jurisdiction outside Australia, including the United States or in relation to any US person (as defined in Regulation S under the U.S Securities Act of 1933, as amended). Any failure to comply with such restrictions may violate applicable securities law.

No party other than the Company has authorised, permitted or caused the issue, submission, dispatch or provision of this presentation, or takes any responsibility for, or makes or purports to make any statement, representation or undertaking in this presentation and there is no statement in this presentation that is based on any statement by any other party. No person, either as a director, partner of or in the employment of the Company has any authority to make, imply, or give any representation or warranty whatsoever in relation to the information contained in this presentation. None of the Careteq Parties take any responsibility for any information in this presentation or any action taken by you on the basis of such information.


To the maximum extent permitted by law, the Careteq Parties:

- exclude and disclaim all liability, including (without limitation) any liability for fraud or negligence, for any
 expenses, losses, damages or costs incurred either as a result of the information in this presentation being
 inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation; and
- make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.

Company Overview

CARETEQ has developed a comprehensive SaaS-based solution and is an early mover in the rapidly growing Assistive Living Technology sector.

- Solutions targeting acute, aged, disability and home care sectors
- Suite of devices for monitoring activity, safety and medication adherence that connect to cloud-based Sofihub platform
- Intuitive and enterprise level central dashboard to manage and control a comprehensive range of Assistive Living Technology solutions
- Peace of mind for users, family and care givers
- Provides Medication Management services to some of the nation's largest aged care providers



2022 Year of Accomplishments

POSITIONING FOR A STEP-CHANGE IN GROWTH

2022 **2023**

Collaboration with RMIT Uni for new innovations

Maiden revenue from US market

Signs 15-yr Exclusive Agreement for Strong Care

Pipeline for Sofihub & **Strong Care** expanding rapidly

Wins first **Strong Care** Customer

Expands Sofihub ecosystem with Carer Light smart device

Our Results

MOMENTUM BUILDING



Revenue

FY22 operating revenue jumped to 502% to \$4.4m and subscriber base lifted 25% to ~3,500



Stable Bottom Line

Net loss only increased to \$5.3m (vs. FY21 loss of \$5.1m) despite significant investments to scale the business and one-off acquisition/listing costs



Growth

Rapidly growing sales pipeline and strong balance sheet put Careteq at a potential growth inflection point in FY23



Opportunities


New opportunity to sell Careteg's solution to the large and lucrative Lone Worker Market via existing channel partner

FY22 was a foundation year for the Group following its listing on the ASX in January 2022

	FY22	FY21	Comments
SaaS Subscriptions	\$220,969	\$59,916	Focus on recurring revenue is paying off
Hardware Sales	\$311,880	\$675,526	More attractive hardware pricing to drive subscriber growth
Ward MM Sales	\$3,895,613	N/A	Ward MM acquired in Aug 2021 with further organic growth expected in FY23
Operating Revenue	\$4,428,462	\$735,442	
Net Loss	\$5,250,091	\$5,112,674	

Solid Performance from Ward MM

FURTHER GROWTH IN FY2023



Market Leading Medication Management Business - Ward MM

- Largest medication management database in Australia with 350+ residential aged care (RAC) facilities and 34,000+ beds
- Acquired by Careteg in August 2021
- 3-year average contract term with high renewable rate and low churn
- Ability to bundle Assistive Living Tech solutions to offer more comprehensive range of services to individuals and RACs















Expanding Pipeline of Opportunities

REACHING FOR FY2023 INFLECTION POINT



Pipeline expands 120% over previous quarter to 165 in 1QFY23 with further growth expected

Receiving interest from a wide-range of industries in US and Australia Benefiting from macro tailwinds (e.g. staff/funding shortage, quality of care challenges, ageing demographics and trend towards in-home care) Receiving more requests for meetings than refusals shows relatively limited competition (especially in US) and growing need for Assistive Living Tech solutions Converting just one lead to binding sales may significantly grow Careteq's subscriber base due to size of many potential clients in the pipeline



Exclusive Agreement: SensorsCall



EXTENDING THE SOFIHUB ECOSYSTEM

Exclusive Agreement

Careteg signs exclusive Australian agreement with US-based SensorsCall.Inc for the Carer Light home platform

Ease of Use

The Carer Light system plugs into a wall socket for monitoring, communication and medication reminders

NDIS Funding

Carer Light qualifies for NDIS funding through Careteg

Networking

Multiple Carer Light devices can be networked across a home

Complementary

Complementary to other Sofihub devices, such as falls detection and safety pendant



Strong Demand for Strong Care

PUSH-PULL GROWTH FACTORS FOR DIGITAL MEDICATION MANAGEMENT



Strong Care

Careteq signed first Strong Care client (360-bed facility) in 1QFY23



Funding

Government funding* applies to StrongCare solution



Growing Opportunities

Pipeline with another 11 opportunities (>3k beds) and growing



Market Leading

Strong Care is one of the most cost effective and fully featured solutions in the market




Synergies

Large cross-selling opportunity through Ward MM which has 34k+ beds under contract



Exclusive Agreement

Careteq has a 15-year exclusive agreement to sell Strong Care in Australia



Fed gov is providing funding* to RACSs until Dec 2024 to transition to digital

> RACSs will have to pay for transition after Dec 2024 **AND** those who don't may not qualify for some gov funded programs

First Data Flow Agreement

VALUE IN CARETEQ'S BIG DATA

Ward MM Database

A global pharmaceutical is paying to access Ward MM medication database for a one-off study

New Opportunities

The study is to evaluate utilisation of recommended National Immunisation Program vaccines

Intrinsic Value

Modest contract value for this study but highlights the latent value of Careteq's datasets to 3rd parties to undertake other types of studies/research



SiTa Foundation Update

PROGRESSING TOWARDS TRIALS



Prototype

SOS device prototype ready for first US trial following improved hardware design



Saas

Careteq providing backend SaaS (Sofihub) while SiTa is working with a 3rd party on the hardware



Recurring Revenue

Under the partnership, Careteq will attract recurring revenue streams on a per device basis



SiTa Founder

SiTa is founded by Jo Natauri, global head of private healthcare and investing at Goldman Sachs in NY and she also serves on the Committee for Corporate Investment and the Sustainable Investing Committee at Goldman



Domestic Violence

~10m Americans adults face domestic violence a year and domestic violence hotlines get >19,000 calls a day




Market Strategy

SiTa is responsible for all trials and go-to-market strategy

The SiTa Foundation is a non-profit organisation, based in the United States, that prepares victims of violence to rise up against repeated abuse by empowering them, building confidence, and increasing safety through the use of technology that engages allies







Springboard into FY2023

POSITIONING FOR A STEP-CHANGE



FY22 Foundation Year

- · Recorded 6-fold increase in operating revenue to \$4.4m
- Invested heavily to build US & Australia sales pipeline
- Growing and "sticky" subscriber base (+25% to ~3,500 with low churn)
- Ward MM acquisition has scaled the business and provided significant revenue growth opportunities

FY23 Inflection Point

- Expecting improved results in FY23 despite slowdown in sales process post-pandemic
- Rapid expansion in sales pipeline with 165 active opportunities and growing
- Sales and technology partnerships (e.g. Seniors.com, Strong Care, etc) to support growth
- Careteg positioned to benefit from the digital evolution unfolding in the aged and disability care sector

Key Earnings Drivers

DEFENSIVE INCOME WITH MULTIPLE GROWTH

FY2023 Earnings Growth Contributors

Subscriptions

SofiHub Subscriber Growth

- Growing demand for Assistive Living Tech solutions
- Large and growing sales pipeline in US and ANZ
- Key partnerships to bolster tech offering and sales efforts
- TAM valued at \$22.7bn (Australia) & \$1.1tn (globally)1

Lone Worker Market

- New opportunity not in initial plans
- Low cost to serve as it uses existing channel partners
- Global market growing at 12.4% CAGR to hit US\$1.6bn by 2027²

Contracted Revenues

Strong Care

- Strong incentives to drive adoption of digital medication management system
- Low cost as sales done through existing network & running/support expenses borne by Strong Room Al
- There are ~250k-300k RACS beds across Australia
- 15-yr (5+5+5) binding exclusive agreement

Ward MM

- Profitable business unit and one of Australia's largest medication management businesses
- 34k+ beds under contract and servicing most of the largest Aged Care providers
- Contracts are 3-year average
- Able to leverage scale to drive organic growth

Data Services

- Data from Ward MM and Sofihub
- Contract with Pfizer demonstrates this

Additional Opps

Future Growth

SiTa Foundation Project

- Potential to add significant number of subs to platform if trial successful
- Low cost to serve as SiTa manages operations

Hospital-in-the-Home

- Careteg is in discussions with prominent healthcare groups within Australia
- Logical extension of Careteq's solution suite to offer vital sign monitoring and technology solutions
- Hospital in the Home found to save cost and produce better health outcomes³
- Global market estimated to be worth US\$336bn in 2021 and growing at 7.9% CAGR (2022-2030)4

¹https://www.globenewswire.com/news-release/2021/07/15/2263455/0/en/Global-Disabled-and-Elderly-Assistive-Technology-Market-to-Reach-32-Billion-by-2026.html

²https://www.reportlinker.com/p06169073/Emergency-Services-for-Lone-Worker-s-Safety-Market-Research-Report-by-Type-by-Component-by-Deployment-by-Region-Global-Forecast-to-Cumulative-Impact-of-COVID-19.html ³https://www.westernsydney.edu.au/__data/assets/pdf_file/0007/1036609/Issues_Paper_-_Taking_Healthcare_Home_Ideas_Lab_23_Feb_2016.pdf

⁴ https://www.grandviewresearch.com/industry-analysis/home-healthcare-industry

Deep Experience in Health Care

BOARD DIRECTORS



Mark Simari Executive Chairman

Over 14 years' Board experience in a diverse range of organisations

Former Managing Director and Co-Founder of Paragon Care (ASX: PGC) (between 2008 and 2018). He was instrumental in Paragon Care becoming one of the largest independent healthcare suppliers in Australian and New Zealand market

Extensive experience in finance, investment, equity capital markets and M&A



Alex Boyd Executive Director / COO

Over two decades of experience in operations, procurement and resource management, concentrating on developing technology solutions

International executive with a background running transformation and growth programs for blue chip companies in multiple sectors

Held senior roles at Shell (LON: RDSA), Parsons, Inc. (NYSE: PSN) and Idox Plc (LON: IDOX)



Brett Cheong Non-Executive Director

Over 40 years of background experience within the healthcare industry at all levels of management

Founder and Managing Director of Axishealth Pty Ltd for 9 years including the role of Marketing Manager.

Extensive management skills focusing on Sales & Marketing, Product Design & Development, Manufacturing and International product sourcing



Stephen Munday Non-Executive Director

Over 40 years business experience in Australia and North America including Chief Financial Officer & Company Secretary positions in several listed companies

Extensive experience in marketing, business development, supply management, commercial management, financial management, change management, compliance and governance

Current Chief financial Officer of Paragon Care Limited

Summary

POSITIVE OUTLOOK FOR 2023 & BEYOND



Growth

FY23 inflection year with potential step-change in growth



Growth Options

Multiple near-term growth options (including new markets) to build scale in Australia and internationally



Momentum

Growth momentum from FY22 expected to accelerate in FY23



Prospective Customers

High levels of interest from prospective customers indicate further growth in sales pipeline



Disruption

Aged and disability care ripe for technological disruption



Macro Tailwinds

Operating in fast growing sector that's benefiting from several macro tailwinds



Thank You

MARK SIMARI

Executive Chairman mark.simari@careteq.com.au

BRENDON LAU

Investor Relations brendon@vantagepointpartners.com.au

CORPORATE ADDRESS

CARETEQ

Level 8

525 Flinders Street

Melbourne 3000

